Literature DB >> 2409935

Fibrolamellar carcinoma of the liver. Review of three cases and the presentation of a characteristic set of tumor markers defining this tumor.

D H Teitelbaum, S Tuttle, L C Carey, K P Clausen.   

Abstract

This study demonstrates the unique clinical and histologic aspects of fibrolamellar hepatic carcinoma, a rare variant of hepatocellular carcinoma. Three cases are reviewed and an extensive study of immunologic and intracellular substances defining this tumor is presented. Length of survival was considerably longer than typical hepatoma. The cause of death generally is due to a lack of control of the primary tumor. Successful treatment appears to relate to the ability to perform a total excision of the primary hepatic tumor. Chemotherapy should be used only in the presence of metastatic disease. Surgical resection of metastatic disease, unlike the usual hepatocarcinoma, may have some beneficial use. Fibrinogen was found in all tumors. It is possible that this tumor produces fibrinogen to create its unique histologic appearance. Carcinoembryonic antigen is described for the first time in this tumor. Both deposits of alpha-1 antitrypsin and copper were found in most of the tissues studied. The presence and amounts of these substances differ markedly from the common type of hepatoma. This unique composition of intracellular components may both facilitate histologic diagnosis, particularly if the amount of tissue is limited, and give further insight into the etiology of this tumor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2409935      PMCID: PMC1250833          DOI: 10.1097/00000658-198507000-00005

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  18 in total

1.  Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.

Authors:  G Falkson; C G Moertel; P Lavin; F J Pretorius; P P Carbone
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

2.  Treatment of osteogenic sarcoma. II. Aggressive resection of pulmonary metastases.

Authors:  S A Rosenburg; M W Flye; D Conkle; C A Seipp; A S Levine; R M Simon
Journal:  Cancer Treat Rep       Date:  1979-05

Review 3.  Localization of hepatitis B virus antigens in hepatocellular carcinoma.

Authors:  T Nazarewicz-de Mezer; J Slusarczyk; K Krawczynski; A Nowoslawski
Journal:  Prog Med Virol       Date:  1981

4.  Pulmonary resection in metastatic carcinoma.

Authors:  P M McCormack; M S Bains; E J Beattie; N Martini
Journal:  Chest       Date:  1978-02       Impact factor: 9.410

5.  Ground-glass cells in hepatocellular carcinoma.

Authors:  F W Stromeyer; K G Ishak; M A Gerber; T Mathew
Journal:  Am J Clin Pathol       Date:  1980-09       Impact factor: 2.493

6.  Hepatocellular carcinoma. Polygonal cell type with fibrous stroma--an atypical variant with a favorable prognosis.

Authors:  M M Berman; N P Libbey; J H Foster
Journal:  Cancer       Date:  1980-09-15       Impact factor: 6.860

7.  Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features.

Authors:  J R Craig; R L Peters; H A Edmondson; M Omata
Journal:  Cancer       Date:  1980-07-15       Impact factor: 6.860

8.  Distribution of five antigens in hepatocellular carcinoma.

Authors:  S N Thung; M A Gerber; E Sarno; H Popper
Journal:  Lab Invest       Date:  1979-08       Impact factor: 5.662

9.  A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States.

Authors:  C L Vogel; A C Bayley; R J Brooker; P P Anthony; J L Ziegler
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

10.  Carcinoembryonic antigen in hepatocellular cancer.

Authors:  G M Macnab; J M Urbanowicz; M C Kew
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

View more
  7 in total

1.  Mediastinal metastasis from a fibrolamellar hepatocellular carcinoma: Report of a case.

Authors:  Yoshinobu Ichiki; Kenji Sugio; Tetsuro Baba; Makiko Mizukami; Takeshi Oga; Mitsuhiro Takenoyama; Takeshi Hanagiri; Koji Okamoto; Koji Yamaguchi; Satoshi Katagiri; Masakazu Yamamoto; Kosei Yasumoto
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

Review 2.  [Diagnosis and differential diagnosis of hepatocellular carcinoma].

Authors:  U Drebber; H P Dienes
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

Review 3.  Fibrolamellar hepatocellular carcinoma. Case reports and a review of the literature.

Authors:  S Saab; F Yao
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

4.  Fibrolamellar carcinoma of the liver--a case report.

Authors:  T Imai; H Yokoi; T Noguchi; Y Kawarada; R Mizumoto
Journal:  Gastroenterol Jpn       Date:  1991-06

5.  Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma.

Authors:  Laura E Moreno-Luna; Oscar Arrieta; Jorge García-Leiva; Braulio Martínez; Aldo Torre; Misael Uribe; Eucario León-Rodríguez
Journal:  BMC Cancer       Date:  2005-10-31       Impact factor: 4.430

Review 6.  Fibrolamellar carcinoma: 2012 update.

Authors:  Michael Torbenson
Journal:  Scientifica (Cairo)       Date:  2012-09-23

Review 7.  Fibrolamellar hepatocellular carcinoma: current clinical perspectives.

Authors:  Kelly J Lafaro; Timothy M Pawlik
Journal:  J Hepatocell Carcinoma       Date:  2015-10-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.